Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study.
We examined oral contraceptive (OC) and menopausal hormonal therapy (MHT) use in relation to risk of B-cell non-Hodgkin lymphoma (NHL). Women under age 85 years participating in the California Teachers Study with no history of hematopoietic cancer were followed from 1995 through 2007. A total of 516 of 114,131 women eligible for OC use analysis and 402 of 54,758 postmenopausal women eligible for MHT use analysis developed B-cell NHL. Multivariable adjusted and age stratified Cox proportional hazards models were fit to estimate relative risks (RRs) and 95% confidence intervals (95% CI). Ever versus never OC use was marginally associated with lower B-cell NHL risk, particularly among women first using OCs before age 25 years (RR=0.72, 95% CI=0.51-0.99); yet, no duration-response effect was observed. No association was observed for ever versus never MHT use among postmenopausal women (RR=1.05, 95% CI=0.83-1.33) overall or by formulation (estrogen alone, ET, or estrogen plus progestin, EPT). Among women with no MHT use, having bilateral oophorectomy plus hysterectomy was associated with greater B-cell NHL risk than having natural menopause (RR=3.15, 95% CI=1.62-6.13). Bilateral oophorectomy plus hysterectomy was not associated with risk among women who used ET or EPT. These results indicate that exogenous hormone use does not strongly influence B-cell NHL risk.
Lu
Yani
Y
Department of Population Sciences, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA. yalu@coh.org
Wang
Sophia S
SS
Sullivan-Halley
Jane
J
Chang
Ellen T
ET
Clarke
Christina A
CA
Henderson
Katherine D
KD
Ma
Huiyan
H
Duan
Lei
L
Lacey
James V
JV
Deapen
Dennis
D
Bernstein
Leslie
L
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002140:California / Q000453:epidemiology; D015331:Cohort Studies; D003276:Contraceptives, Oral / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000139:chemically induced / Q000453:epidemiology / Q000628:therapy; D016393:Lymphoma, B-Cell / Q000139:chemically induced* / Q000453:epidemiology / Q000628:therapy; D008224:Lymphoma, Follicular / Q000139:chemically induced / Q000453:epidemiology / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced / Q000453:epidemiology / Q000628:therapy; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
D003276:Contraceptives, Oral